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Abstract
Non-alcoholic fatty liver disease (NAFLD) is common and strongly associated with the meta-
bolic syndrome. Though NAFLD may progress to end-stage liver disease, the top cause of
mortality in NAFLD is cardiovascular disease (CVD). Most of the data on liver-related mor-
tality in NAFLD derives from specialist liver centres. It is not clear if the higher reported mor-
tality rates in individuals with non-cirrhotic NAFLD are entirely accounted for by
complications of atherosclerosis and diabetes. Therefore, we aimed to describe the CVD
burden and mortality in NAFLD when adjusting for metabolic risk factors using a ‘real world’
cohort. We performed a retrospective study of patients followed-up after an admission to
non-specialist hospitals with a NAFLD-spectrum diagnosis. Non-cirrhotic NAFLD and
NAFLD-cirrhosis patients were defined by ICD-10 codes. Cases were age-/sex-matched
with non-NAFLD hospitalised patients. All-cause mortality over 14-years follow-up after dis-
charge was compared between groups using Cox proportional hazard models adjusted for
demographics, CVD, and metabolic syndrome components. We identified 1,802 patients
with NAFLD-diagnoses: 1,091 with non-cirrhotic NAFLD and 711 with NAFLD-cirrhosis,
matched to 24,737 controls. There was an increasing burden of CVD with progression of
NAFLD: for congestive heart failure 3.5% control, 4.2% non-cirrhotic NAFLD, 6.6% NAFLD-
cirrhosis; and for atrial fibrillation 4.7% control, 5.9% non-cirrhotic NAFLD, 12.1% NAFLD-
cirrhosis. Over 14-years follow-up, crude mortality rates were 14.7% control, 13.7% non-cir-
rhotic NAFLD, and 40.5% NAFLD-cirrhosis. However, after adjusting for demographics,
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non-cirrhotic NAFLD (HR 1.3 (95% CI 1.1–1.5)) as well as NAFLD-cirrhosis (HR 3.7 (95%
CI 3.0–4.5)) patients had higher mortality compared to controls. These differences remained
after adjusting for CVD and metabolic syndrome components: non-cirrhotic NAFLD (HR 1.2
(95% CI 1.0–1.4)) and NAFLD-cirrhosis (HR 3.4 (95% CI 2.8–4.2)). In conclusion, from a
large non-specialist registry of hospitalised patients, those with non-cirrhotic NAFLD had
increased overall mortality compared to controls even after adjusting for CVD.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in Europe [1] and
is strongly associated with all features of the metabolic syndrome [2]. The majority of patients
with NAFLD have simple steatosis (non-alcoholic fatty liver, NAFL) and only a minority have
non-alcoholic steatohepatitis (NASH), with or without fibrosis. However a small, but signifi-
cant proportion do progress to end-stage liver disease [3].
NAFLD is thought to be associated with increased all-cause and cardiovascular mortality
[4–6]. It has been established that fibrosis is the main predictor of long-term liver-related mor-
bidity in NAFLD [3, 7–9] and that patients with NASH but no fibrosis have a similar outcome
to those with NAFL and no fibrosis. However, these studies included biopsy-proven patients
in specialist clinics and therefore there is likely significant ascertainment bias in estimating
rates of hepatic complications. Recent data also suggests that fibrosis stage is a critical predictor
of cardiovascular events in NAFLD [10]. The natural history of NAFLD and its impact upon
clinical services is an important topic that divides expert opinion [11, 12].
Cardiovascular disease (CVD) is the commonest cause of mortality in patients with
NAFLD [3]. A recent large-scale analysis strongly suggests that this is due to prevalence of clas-
sical CVD risk factors such as type 2 diabetes and dyslipidaemia [13]. Insulin resistance is
understood to be the primary driver linking all these features of the metabolic syndrome. In
response to the positive energy balance of obesity, subcutaneous adipose becomes dysfunc-
tional and there is expansion of visceral white adipocytes, which are less insulin sensitive and
have a higher basal rate of lipolysis [14]. Elevated insulin and increased substrate delivery to
the liver promotes hepatic steatosis by driving increased de novo lipogenesis without increasing
glucose uptake [15]. Cumulatively, this results in a rise in circulating triglycerides, impaired
low-density lipoprotein clearance, and higher serum glucose. Hepatic steatosis is also thought
to alter the composition of secreted lipoparticles [16].
A further increasingly important consideration is the burden of cardiovascular co-morbid-
ity in patients with end-stage NAFLD for whom transplantation is an option [17]. There is cur-
rently comparatively limited data on the prevalence of CVD in patients with NAFLD cirrhosis
[18]. One study of 133 patients with cryptogenic cirrhosis found nearly half to have diabetes
and 18% had experienced a major cardiovascular or cerebrovascular event [19]. CVD events
are common post-transplant sequelae and chronic kidney disease is linked to reduced graft
survival [20].
Whilst several previous natural history studies have included comparison to age- and gen-
der-matched control populations, they have been unable to control for CVD [21–23]. There-
fore, it remains unclear whether NAFLD is associated with increased all-cause mortality after
correction for cardiac and metabolic disease risk factors.
We aimed to first describe the burden of CVD across the NAFLD disease spectrum: non-
cirrhotic-NAFLD and NAFLD-cirrhosis (end-stage fibrosis). Then to assess whether they are
associated with increased all-cause mortality in a real life cohort of hospitalised UK patients
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from the ACALM (Algorithm for Comorbidities, Associations, Length of stay and Mortality)
registry, after correction for CVD and metabolic risk factors.
Materials and methods
Study design
The study was conducted as a retrospective cohort study of adult patients in England during
2000–2013 who were admitted to 7 different hospitals with naturalistic follow-up. All available
data was included. Tracing of anonymised patients was performed using the ACALM (Algo-
rithm for Comorbidities, Associations, Length of stay and Mortality) study protocol to develop
the ACALM registry and has been previously described by our group [24–29]. Briefly, medical
records were obtained from local health authority computerized Hospital Activity Analysis
register, which is routinely collected by all NHS hospitals. This provides fully anonymized data
on hospital admissions and allows for the long-term tracing of patients at an individual hospi-
tal. The ACALM protocol uses the International Classification of Disease, 10th edition (ICD-
10) and Office of Population Censuses and Surveys Classification of Interventions and Proce-
dures (OPCS-4) coding systems to trace patients. This data was obtained separately for the
seven included hospitals. Similar data could be obtained through national Hospital Episode
Statistics or from any local Hospital Activity Analysis register.
Participant identification
ICD-10 codes were used to identify patients with NAFL (non-alcoholic fatty liver, K76.0),
NASH (non-alcoholic steatohepatitis, K75.8), and NAFLD-cirrhosis (cryptogenic cirrhosis,
K74.6). Where a patient was coded with both NAFL and NASH, they were included in the
NASH group. Patients coded with both NAFL and NAFLD-cirrhosis, or NASH and NAFLD-
cirrhosis, were included in the cirrhosis group. NAFL and NASH groups were combined to
create a non-cirrhotic-NAFLD group. As per UK practice, the diagnosis of NAFL, NASH, or
NAFLD-cirrhosis were made according to clinical judgement and the latest guidelines but the
results of the investigations used to derive the diagnoses were not available. An age- and sex-
matched control group (with no liver-related diagnoses) was identified from the same
ACALM registry and matched 10:1 to patients with NAFLD diagnoses. In line with recent rec-
ommendations [30], patients with a history of alcohol excess (F10) or any other alcohol-related
diagnosis were excluded. In addition, patients with other liver diseases were excluded, includ-
ing: autoimmune hepatitis (K75.4), viral hepatitis (B15-B19), Wilson disease and haemochro-
matosis (E83), cholangitis (K83.0) and primary biliary cirrhosis (K74.3).
Data collection
All of these patients were then assessed for the presence of several cardiovascular co-morbidi-
ties and risk factors, including: congestive heart failure (CHF, I150.0), atrial fibrillation (I48),
and non-insulin dependent diabetes mellitus (NIDDM, E11), chronic kidney disease (N18),
obesity (E66.0), myocardial infarction (I21-I22), ischaemic heart disease (I20-25), ischaemic
stroke (I63.9), hyperlipidaemia (E78.5), hypertension (I10), and peripheral vascular disease
(I73.9). Prevalence of malignancy was collected using codes C0-C9. Patients were also assessed
for liver-related events: hepatocellular carcinoma (HCC, C22.9), hepatic failure (K72), oeso-
phageal varices (I85), portal hypertension (K76.6), splenomegaly (R16.1), and ascites (R18). A
combined ‘hepatic decompensation or failure’ score was generated from the sum of all non-
malignant liver-related events. Inclusion of hepatic encephalopathy (K72.9) or variceal
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bleeding (I98.3, I98.8, I85.9) did not identify any additional patients. Jaundice was not
included due to identification of patients with obstructive (non-hepatic) jaundice.
Vital status (alive or deceased) on 31st March 2013 was determined by record linkage to the
National Health Tracing Services (NHS strategic tracing service) and was received along with
the raw data; this was used to calculate all-cause mortality and survival. The first admission to
hospital treatment was chosen as index admission, follow-up of patients continued until 31st
March 2013.
Approvals
Confidentiality of information was maintained in accordance with the UK Data Protection
Act. The patient data included was fully anonymous and non-identifiable when received by
the authors, and collected routinely by the hospitals. Therefore, according to local research
ethics policies we were not required to seek formal ethical approval for this study.
Statistical analysis
Data analysis was performed using SPSS version 20.0 (SPSS Inc. Chicago, IL), R version 4.0.2,
and GraphPad Prism version 8.0. Code used in analyses in R is available in the S1 File. Analy-
ses were initially performed by comparing three groups: control, non-cirrhotic NAFLD
(NAFL plus NASH), and NAFLD-cirrhosis. Clinical outcomes were compared between groups
using chi-squared tests for categorical variables and t-tests for age. Multivariate logistic regres-
sion was used to determine adjusted odds ratios for hepatic failure/decompensation and hepa-
tocellular carcinoma, adjusted for demographics (age, gender, ethnicity). Cox regression
analysis was used to determine adjusted hazard ratios (HR) for overall mortality between
groups. Cox regression was performed using four models: 1) adjusting for variations in demo-
graphics (age, gender, ethnicity); 2) adjusting for demographics plus CVD or metabolic risk
factors (obesity, NIDDM, CHF, ischaemic stroke, myocardial infarction, chronic kidney dis-
ease, peripheral vascular disease, hypertension, hyperlipidaemia, ischaemic heart disease, and
atrial fibrillation); 3) adjusting for demographics plus liver-related events (hepatocellular carci-
noma, hepatic failure, oesophageal varices, portal hypertension, splenomegaly, and ascites);
and 4) adjusting for demographics, CVD, metabolic risk factors, and liver-related events. Par-
ticipants with incomplete data were excluded. Cumulative hazard survival curves were derived
using Cox proportional regression models. A supplementary analysis was performed using
four groups, by splitting the non-cirrhotic NAFLD group into NAFL and NASH: control,
NAFL, NASH, and NAFLD-cirrhosis. All analyses from the main analyses were replicated for
these four groups.
A further sub-analysis was performed by removing all participants with liver-related events
and then calculating adjusted mortality hazard ratios using Cox regression adjusted for 1)
demographics only, and 2) demographics, CVD, and metabolic risk factors.
Two-sided p-values were calculated for all statistical tests and then corrected for multiple
testing using the Benjamini-Hochberg method. Q-values <0.05 were considered significant.
Results
1,802 patients were identified with NAFLD-spectrum diagnoses, of which 1,091 had non-cir-
rhotic NAFLD (994 with NAFL and 97 with NASH) and 711 with NAFLD-cirrhosis (Table 1
and S1 Table). They were matched to 24,737 hospitalised in-patient controls. The median
duration of follow-up for each group was: control 5.3 years, NAFL 4.6 years, NASH 4.4 years,
and cirrhosis 2.8 years (range 1 day—14 years for all groups).
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The control group was older than the non-cirrhotic NAFLD group (55 years vs. 52 years,
q = 6.4x10-12) but younger than the cirrhosis group (55 years vs. 64 years, q = 2.0x10-62). The
non-cirrhotic NAFLD group had a higher proportion of participants self-identifying as South
Asian (6.6% control vs. 12.8% non-cirrhotic NAFLD, q = 4.6x10-14).
Patients with non-cirrhotic NAFLD had a higher prevalence of metabolic risk factors
(hyperlipidaemia, type 2 diabetes mellitus, obesity, and hypertension) than controls (Table 2),
despite being younger. There were no differences between NAFL and NASH groups on sub-
analysis (S2 Table). Compared to the NAFLD group, patients with cirrhosis were more likely
to have T2DM (22% NAFLD vs. 35% cirrhosis, q = 8.7x10-10) but had a lower prevalence of
hyperlipidaemia (13.3% NAFLD vs. 6.5% cirrhosis, q = 1.4x10-5).
There was an increasing burden of cardiovascular co-morbidity with more advanced liver
disease. Compared to the control group, patients with NASH had a higher prevalence of heart
failure (10.5% vs. 3.5%, q = 4.5x10-3, S2 Table). The cirrhosis group showed higher prevalence
of atrial fibrillation and CKD compared to the NAFLD group (Table 2). No differences in
prevalence of ischaemic stroke were observed.
Table 1. Demographics for control, non-cirrhotic-NAFLD and NAFLD-cirrhosis patients.
Control
(n = 24,737)
NAFLD
(n = 1,091)
NAFLD vs. Control q-
value
Cirrhosis
(n = 711)
Cirrhosis vs. Control q-
value
Cirrhosis vs. NAFLD q-
value
Mean age
(SD)
55.0 (15.4) 51.6 (15.2) 6.4E-12 63.6 (13.5) 2.0E-53 2.0E-62
Female 10,999 (44.5) 518 (47.5) 0.09 338 (47.5) 0.15 1
Caucasian 19,761 (79.9) 850 (77.9) 0.17 607 (85.4) 6.5E-04 2.10E-04
South Asian 1,652 (6.7) 140 (12.8) 4.6E-14 37 (5.2) 0.17 4.70E-07
Baseline demographics for participants included in the study. Q-values were derived from chi-squared tests (for sex and ethnicity) or t-tests (for age) with adjustment
for multiple testing using the Benjamini-Hochberg method. SD, standard deviation.
https://doi.org/10.1371/journal.pone.0241357.t001
Table 2. Cardiovascular disease burden and liver-related events across the NAFLD spectrum.
Control
(n = 24,737)
NAFLD
(n = 1,091)
NAFLD vs. Control q-
value
Cirrhosis
(n = 711)
Cirrhosis vs. Control q-
value
Cirrhosis vs. NAFLD q-
value
Obesity 307 (1.2) 92 (8.4) 3.6E-77 27 (3.8) 2.0E-08 2.8E-04
Type 2 Diabetes 2328 (9.4) 235 (21.5) 4.2E-38 250 (35.2) 3.3E-110 8.7E-10
Hyperlipidaemia 2015 (8.1) 145 (13.3) 7.6E-09 46 (6.5) 0.16 1.4E-05
Hypertension 5655 (22.9) 343 (31.4) 2.2E-10 225 (31.6) 1.1E-07 1
Ischaemic heart disease 2951 (11.9) 115 (10.5) 0.24 112 (15.8) 4.0E-03 2.2E-03
Myocardial infarction 940 (3.8) 24 (2.2) 0.02 21 (3.0) 0.33 0.48
Atrial fibrillation 1174 (4.7) 64 (5.9) 0.16 86 (12.1) 3.3E-18 1.1E-05
Congestive Heart Failure 865 (3.5) 44 (4.0) 0.45 63 (8.9) 2.7E-13 7.4E-05
Ischaemic stroke 498 (2.0) 12 (1.1) 0.08 24 (3.4) 0.03 2.2E-03
Peripheral vascular disease 381 (1.5) 13 (1.2) 0.47 14 (2.0) 0.49 0.33
Chronic Kidney Disease 309 (1.2) 23 (2.1) 0.04 33 (4.6) 8.8E-14 5.5E-03
Any malignancy 1876 (7.6) 103 (9.4) 0.05 176 (24.8) 1.2E-60 1.1E-17
GI malignancy 395 (1.6) 38 (3.5) 9.4E-06 111 (15.6) 3.4E-151 6.6E-19
Hepatic failure/
decompensation
116 (0.5) 61 (5.6) 1.3E-86 300 (42.2) <1E-300 1.0E-78
Hepatocellular carcinoma 45 (0.2) 14 (1.3) 4.5E-12 93 (13.1) <1E-300 6.5E-24
All-cause mortality 3,635 (14.7) 149 (13.7) 0.44 288 (40.5) 1.9E-225 5.9E-91
Crude rates of mortality, metabolic, cardiovascular, and liver-related outcomes for control, non-cirrhotic-NAFLD, and NAFLD-cirrhosis, patients during a 14-year
study period. Q-values were derived from chi-squared tests with adjustment for multiple testing using the Benjamini-Hochberg method.
https://doi.org/10.1371/journal.pone.0241357.t002
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The prevalence of hepatic events (hepatic failure or decompensation and development of
hepatocellular carcinoma (HCC)) was higher in all groups of patients with NAFLD (Table 2)
and was similar between NAFL and NASH groups (S2 Table). The increased prevalence of
liver-related events remained after adjustment for age, sex, and ethnicity (Table 3).
Unadjusted 14-year all-cause mortality was 14.7% for patients in the control group, 13.7%
for patients with non-cirrhotic NAFLD, and 40.5% for those with NAFLD-cirrhosis (Table 2).
However, the control group were significantly older than those with non-cirrhotic NAFLD,
therefore after adjustment for age, gender and ethnicity, all-cause mortality hazard ratio was
higher in the non-cirrhotic NAFLD group compared to the control group (HR 1.3 (95% CI
1.1–1.5), q = 3.7x10-3, Table 3 and Fig 1A). After adjustment for cardiovascular factors, all-
cause mortality was still elevated compared to the control group: non-cirrhotic NAFLD HR
1.2 (95% CI 1.0–1.4, q = 0.04, Fig 1B) and NAFLD-cirrhosis HR 3.4 (95% CI 2.8–4.2,
q = 1.1x10-33). However, after adjusting for liver-related events there was no difference in mor-
tality between controls and non-cirrhotic NAFLD patients (HR 1.1 (95% CI 0.9–1.3), q = 0.61,
Fig 1C) but elevated mortality remained for those with NAFLD-cirrhosis (HR 3.0 (95% CI
2.4–3.7), q = 4.8x10-24). No differences in adjusted mortality ratios were observed between
NAFL and NASH groups on sub-analysis (S1 Fig and S3 Table).
After removing patients who had experienced liver-related events (S4 Table), there was no
difference in hazard ratio of mortality for patients with non-cirrhotic NAFLD compared to
control when adjusting for demographics (HR 1.2 (95% CI 1.0–1.4), q = 0.08).
Discussion
This study provides important non-specialist “real life” data amongst hospitalised patients
demonstrating an increased mortality for patients with non-cirrhotic NAFLD, even after
adjustment for CVD. This difference appeared to be due to liver-related events (hepatic
Table 3. Adjusted odds ratios for liver-related outcomes and adjusted mortality hazard ratios.
NAFLD vs. Control Cirrhosis vs. Control Cirrhosis vs. NAFLD
Adj. OR (95%
CI)
q-value Adj. OR (95%
CI)
q-value Adj. OR (95%
CI)
q-value
Hepatic failure/decompensation 2.6 (2.3–2.9) 4.00E-
57
4.9 (4.7–5.2) <1E-300 2.4 (2.1–2.7) 3.60E-
49
Hepatocellular carcinoma 2.2 (1.5–2.7) 1.10E-
11
4.2 (3.8–4.6) 8.30E-
107
1.9 (1.4–2.6) 7.60E-
11
HR (95% CI) q-value HR (95% CI) q-value HR (95% CI) q-value
Mortality adjusted for demographic characteristics 1.3 (1.1–1.5) 3.70E-
03
3.8 (3.4–4.2) 8.30E-
146
3.7 (3.0–4.5) 1.30E-
38
Mortality adjusted for demographics, metabolic risk factors, and CVD 1.2 (1.0–1.4) 0.04 3.2 (2.9–3.6) 8.30E-
107
3.4 (2.8–4.2) 1.10E-
33
Mortality adjusted for demographics and liver-related events 1.1 (0.9–1.3) 0.61 2.4 (2.1–2.8) 2.80E-31 3.0 (2.4–3.7) 4.80E-
24
Mortality adjusted for demographics, metabolic risk factors, CVD, and liver-
related events
1.0 (0.9–1.2) 0.8 2.1 (1.8–2.4) 9.00E-23 2.8 (2.3–3.5) 2.00E-
21
Odds ratios for liver-related events (hepatic failure/decompensation and hepatocellular carcinoma) were calculated using multivariable logistic regression adjusted for
age, sex, and ethnicity. Adjusted hazard ratios of overall mortality were calculated between control, non-cirrhotic NAFLD, and NAFLD-cirrhosis groups using Cox
proportional regression. Adjustment for demographic characteristics were gender, age and ethnicity. Adjustment for metabolic risk factors and CVD included: obesity,
type 2 diabetes mellitus, CHF, ischaemic stroke, myocardial infarction, chronic kidney disease, peripheral vascular disease, hypertension, hyperlipidaemia, ischaemic
heart disease, and atrial fibrillation. Adjustment for liver-related events included: hepatocellular carcinoma, hepatic failure, oesophageal varices, portal hypertension,
splenomegaly, and ascites. Control n = 25,780; NAFLD n = 1,343; and Cirrhosis n = 1,235. Q-values were calculated from p-values using the Benjamini-Hochberg
method. Adj. OR, adjusted odds ratio; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.
https://doi.org/10.1371/journal.pone.0241357.t003
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failure/decompensation and HCC) over a 14 year follow-up period. The size of the cohort and
lack of link to specialist liver centres reduces likelihood of bias. These data will help inform
healthcare demand for this cohort of patients, complementing modelling estimates [31, 32]. In
addition, we have highlighted the burden of CVD in patients with NAFLD-cirrhosis, which
poses a particular issue for transplantation. Whilst all participants in our cohort were hospital-
ised, which may increase their risk of future clinical events, so were the controls, thus the com-
parisons between groups remain valid within this setting.
The strong association between NAFLD and CVD has been well established [33–35]. Rela-
tionships have been identified between NAFLD and heart failure [36], atrial fibrillation [37],
hypertension [38], stroke [39], chronic kidney disease [40], and coronary artery disease.
NAFLD has even been linked to increased mortality in acute heart failure [41]. However
Fig 1. Adjusted cumulative hazard of mortality for hospitalised controls, patients with non-cirrhotic NAFLD, and NAFLD-cirrhosis. Survival curves showing
cumulative hazard of mortality derived from four models of adjustment using Cox proportional regression. Data shows 95% CI for control n = 24,737; NAFLD
n = 1,091; and Cirrhosis n = 711. (A) Adjustment for demographic characteristics only (gender, age and ethnicity). (B) Adjustment for demographics plus CVD and
metabolic risk factors (obesity, type 2 diabetes mellitus, CHF, ischaemic stroke, myocardial infarction, chronic kidney disease, peripheral vascular disease, hypertension,
hyperlipidaemia, ischaemic heart disease, and atrial fibrillation). (C) Adjustment for demographics and liver-related events (hepatocellular carcinoma, hepatic failure,
oesophageal varices, portal hypertension, splenomegaly, and ascites). (D) Adjustment for demographics, CVD, metabolic risk factors, and liver-related events.
https://doi.org/10.1371/journal.pone.0241357.g001
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strong observational data from a large European meta-analysis suggests that NAFLD is not
causal in acceleration of CVD [13]. Our data highlights the particularly increased prevalence
in patients with cirrhosis and is broadly consistent with a previously reported cohort from
Italy [19]. Indeed, hypertension has been highlighted as an independent risk factor for
advanced fibrosis in NAFLD [42]. A further consideration is whether heart failure contributes
to accelerated fibrosis in NAFLD [43], though causality is difficult to establish.
Some previous studies with biopsy-defined cohorts have been smaller, did not adjust for
cardiovascular diagnoses [3, 22], and found no difference in mortality between participants
with NAFLD and no fibrosis, and controls. Kim et al. used NHANES data to stratify patients
by non-invasive fibrosis scores, and again found no increase in mortality in patients with ultra-
sound-defined NAFLD, after correction for diabetes and hypertension [21]. This may be
accounted for by differences in the ethnicity of the cohort and also the general, rather than spe-
cialist, nature of our population. A more recent Italian study in a prospective, consecutively
recruited cohort found that after adjusting for metabolic risk factors patients with NAFLD had
higher rates of cardiovascular events [10]. Moreover, they used non-invasive fibrosis scores to
demonstrate that higher fibrosis stage was associated with increased risk of cardiovascular
events, which is generally consistent with our results from the NAFLD-cirrhosis group. Similar
results were observed in a further biopsy-proven NAFLD cohort of 285 patients [44].
NAFLD may itself be a marker of sub-clinical CVD. For example, increased carotid intima
media thickness has been found in adolescents with NAFLD [45]. This is mechanistically plau-
sible as hepatic steatosis occurs (in part) secondary to peripheral insulin resistance and ele-
vated substrate delivery from lipolysis of adipose tissue. Steatosis itself then contributes to
systemic insulin resistance [14, 46]. Therefore, in this analysis, despite adjusting for metabolic
covariates and cardiovascular risk factors, elevated mortality may reflect the sub-clinical nature
of atherosclerosis associated with NAFLD, even at an early stage.
Given the shared disease mechanisms and clinical outcomes for NAFLD and CVD, these
data suggest a common framework for treatment. Weight loss is the only established treatment
strategy for NAFLD [47] and there is data suggesting that specific dietary regimens (including
the Mediterranean diet) are beneficial [48]. The same lifestyle interventions and aggressive risk
factor modification will have dual impact on reducing cardiovascular [49, 50] and hepatic
events. Statins are likely to be recommended for many patients with NAFLD due to their CVD
risk factors, often in combination with treatment for type 2 diabetes. Given the relative risk of
incident morbidity from CVD compared to liver-related events, these treatments are likely to
primarily influence cardiac events [51, 52]. We were unable to determine drug therapy in the
participants included in this study, which has the potential to influence disease outcomes [53,
54] and therefore should be considered as a limitation of the work.
Whilst we were not able to determine cause of death or admission in our cohort, we were
able to determine that liver decompensation events were increased in all groups relative to the
control group. In addition, excluding participants who had experienced liver-related events,
removed the mortality difference between control and non-cirrhotic NAFLD patients.
This study is limited by its retrospective design and the use of generic coding, which did
not provide information on how the diagnosis was obtained i.e. imaging, liver function tests,
or liver biopsy and we were unable to identify whether NAFLD was the cause of admission or
an existing co-morbidity in cases. Therefore, the sub-analysis for NAFL and NASH groups
should be interpreted with this in mind. However, coding improvements along with standard-
ised diagnosis of NAFLD in the UK means that the impact of inaccurate coding may be low.
ICD-10 coding is likely to be a poorly sensitive method to exclude NAFLD from the control
group, due to the asymptomatic nature of the condition. However this bias would likely result
in an under-estimation of the hazard ratios comparing control and NAFLD groups. The use of
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ICD-10 codes for the exclusion of other causes of liver dysfunction (for example, viral hepati-
tis) and patients with a history of alcohol consumption may have also contributed to inaccu-
rate coding. However, such biases have been limited from our previous study looking at the
association between cardiovascular and respiratory conditions [29]. There is likely to be a
degree of under coding of NAFLD, especially as clinical awareness of NAFLD was not optimal
at the beginning of the data capture [55]. It should be noted that the follow-up in this study
ended in 2013, and since there has been a progressive increase in prevalence of NAFLD as well
as development in non-invasive diagnostic techniques that were not widely available in 2000–
2013 (e.g. elastography)
Our analysis has illustrated that a substantial proportion of participants with cirrhosis have
risk factors for vascular events. Cirrhosis is a state of disordered clotting with patients at
increased risk for thrombosis yet also exhibit hyperfibrinolysis [56]. In this study we were
unable to further examine the characteristics of participants experiencing vascular events due
to a lack of detailed participant-level data.
Whilst the participants with non-cirrhotic NAFLD in this study were from non-specialist
centres, they may still represent a more advanced subset of patients with NAFLD than the
entire population of individuals with hepatic steatosis. We found 5.6% of patients initially
diagnosed with non-cirrhotic NAFLD to experience a liver-related event during 14-years of
follow-up, compared to 7.9% found in the biopsy-staged cohort from Hagstro¨m et al. [7] and
4.2% reported by Angulo et al. [3] The control cohort used in this study were also hospitalised
patients, therefore comparisons using hazard ratios are valid within this setting. However our
results are not generalisable to patients diagnosed with NAFLD outside of a hospital setting.
Similarly, the results comparing non-cirrhotic NAFLD with NAFLD-cirrhosis are likely to
have been influenced by lead time bias. The cirrhosis group were significantly older than non-
cirrhotic NAFLD group and were, by definition, at a more advanced stage in their disease.
Therefore, the NAFLD-cirrhosis results illustrate a highly concentrated group of the most
severe part of the NAFLD spectrum.
In conclusion, these results contribute to our understanding of co-morbidity, mortality and
liver decompensation in patients hospitalised with NAFLD spectrum disease and demonstrates
there is higher mortality independent of known cardiovascular risk factors.
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